NanoViricides entered into an At Market Issuance Sales Agreement with D. Boral Capital to sell common stock from time to time under its shelf registration. Shares may be sold on NYSE American or other markets, or through privately negotiated transactions with the company’s consent. The Sales Agent will receive a 2.0% commission on aggregate gross proceeds. The program provides flexibility to raise equity capital as needed.

Agreement details:

  • Agreement type: At Market Issuance Sales Agreement for at-the-market equity offering
  • Counterparty: D. Boral Capital
  • Signed / Effective: Jul 17 2026 / same
  • Duration / Termination: At will
  • Reason: Raise capital via at-the-market equity program

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.